Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs ENGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: LCTX 4 – 1 ENGN (1 Tie) Matrix Metrics: LCTX 8 – 2 ENGN

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over enGene Holdings Inc. (ENGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas ENGN carries 41.7/100 (SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. ENGN 41.7/100 SELL) and 1.36β · 79% Vol risk profile, whereas ENGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile ENGN trades in a Neutral technical trend (SURGE options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs ENGN
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
ENGN NASDAQ
enGene Holdings Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.76
-4.86% 1D
Market Cap $119.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.96β · 143% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 15.0 Fund 46.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.74 · SMA50: $1.79

6-Pillar Scorecard Institutional Category Breakdown (LCTX 4 – 1 ENGN)

Columns: Metric · LCTX · ENGN
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 16.3x N/M
2. Growth & Scale LCTX
Revenue Growth (YoY) -61.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $212.1M $119.6M
3. Profitability & Quality LCTX
Gross Margin -95.0% N/A
Operating Margin -280.3% 0.0%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -60.5%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$104M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $7.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENGN
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 896.2% (100th %ile) 0.0% (<1st %ile)
Put/Call OI Skew 1.10x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (8) vs ENGN (2)
Institutional Metric LCTX ENGN Criterion Row Edge
Market Capitalization
Scale
$212.1M $119.6M Larger Scale LCTX
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% +0.0% Higher Growth ENGN
Operating Margin (TTM)
Profitability
-280.3% 0.0% Higher Margin ENGN
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -60.5% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 3% ($1–$12) Stronger Trend LCTX
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 1.96β · 143% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$104M ($7.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENGN +21.8 pp
LCTX: -13.82% · ENGN: +7.98%
3M Horizon ENGN +22.95 pp
LCTX: -24.07% · ENGN: -1.12%
6M Horizon ENGN +39.61 pp
LCTX: -37.88% · ENGN: +1.73%
1Y Horizon LCTX +20.75 pp
LCTX: -53.67% · ENGN: -74.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LCTX vs ENGN. Trailing 12-month operating profitability (LCTX -280.3% vs ENGN 0.0%) and valuation multiples (LCTX 30.7x vs ENGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LCTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin-95.0%
Op. Margin-280.3%
ROE / Fwd P/E4.3% · 30.7x
ENGN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-60.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENGN SURGE
5d in phase · OBV ACCUMULATION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact ENGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $119.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs ENGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over enGene Holdings Inc. (ENGN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas ENGN carries 41.7/100 (SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: LCTX earns the overall head-to-head edge with a stronger Unified Composite Score (58.9/100 HOLD vs. ENGN 41.7/100 SELL) and 1.36β · 79% Vol risk profile, whereas ENGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile ENGN trades in a Neutral technical trend (SURGE options phase, RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LCTX leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with ENGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LCTX generates $11M in USD-normalized revenue versus N/A for ENGN. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENGN.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas ENGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus ENGN (-60.5% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, ENGN carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.96β · 143% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.